Company
Melbourne, VIC
Every investor coverage indicates participated in a round Monash Institute of Pharmaceutical Sciences raised.
Companies Monash Institute of Pharmaceutical Sciences acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Monash Institute of Pharmaceutical Sciences. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Manufacturing news roundup: GreenHY2 and Atomo Diagnostics receive government grants, Seaport Therapeutics closes a US$225m Series B, Orthocell secures $17m, Genevo Marine opens a crowdfunding offer, and the ACCC clears Accolade's wine acquisition.
Roundup of Australian manufacturing items: Manildra draws on CEFC money to quit coal, Ankere Therapeutics launches with seed backing, Micro-X gear reaches Ukraine, plus a vessel naming, precinct tenders, an FFI appointment and a cable rebrand.
Biotech startup Ankere Therapeutics launches with a $10 million seed round co-led by IP Group and Brandon Capital to develop inflammatory lung disease therapies, building on research from Monash and UniSA scientists.
Also Brandon Capital portfolio·Startup Daily·@AuManufacturing
IDT Australia has secured an $11.44 million federal government payment to prepare its Melbourne sterile facility for potential mRNA vaccine production, with $7.5 million already received; vaccine candidate talks with Monash continue.
The Victorian government granted Monash Institute of Pharmaceutical Sciences $5 million for mRNA vaccine manufacturing ahead of Phase 1 trials; the vaccine earlier attracted $3 million from the Medical Research Future Fund.
Cincera Therapeutics has received a million-dollar Biomedical Translation Bridge grant to advance its Des-1 inhibitor drug for obesity-related metabolic diseases. The Monash and UniSA spin-out previously secured venture funding from the Medical Research Commercialisation Fund.